[ad_1] Biocon Biologics has completed the integration of Viatris’ biosimilars business across countries in Europe. Credit: Biocon. Biocon subsidiary Biocon Biologics has successfully integrated Viatris‘ biosimilars business in 31 countries…
Tag: Viatris
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
[ad_1] BENGALURU, India, Nov. 30, 2023 /PRNewswire/ — Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business…
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
[ad_1] Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] View PDF Reports…
Overseas Investment Winter For India Inc.
[ad_1] ON AUGUST 22, 2022, the Central government announced a review of overseas investment framework to bring clarity on direct and portfolio investments abroad. It brought various transactions under automatic…
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
[ad_1] Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA View PDF …
Viatris targets ulcerative colitis in Japan with $10M agreement with Swedish pharma InDex
[ad_1] In Amgen’s new oncology video series, patient Gina calls her colorectal cancer diagnosis “the best worst thing that’s ever happened to me.” She goes on to talk about her…